-
公开(公告)号：US20120088819A1
公开(公告)日：2012-04-12
申请号：US13126355
申请日：2009-10-30
申请人： Makoto Inoue , Koichi Saeki , Jun You , Toshiaki Tabata , Hitoshi Iwasaki , Tsugumine Shu , Mamoru Hasegawa
发明人： Makoto Inoue , Koichi Saeki , Jun You , Toshiaki Tabata , Hitoshi Iwasaki , Tsugumine Shu , Mamoru Hasegawa
IPC分类号： A61K31/7088 , C12N5/10 , C12P21/00 , C12N15/63
CPC分类号： C12N15/67 , A61K2039/53 , C07K2319/55 , C12N15/86 , C12N2760/18843
摘要： The present invention provides methods for enhancing protein expression from an RNA viral vector and RNA viral vectors with enhanced protein expression capacity. The present inventors successfully increased the level of protein expression significantly by expressing the proteins fused with an AB5B protein from RNA viral vectors. Effective gene therapy, gene vaccination, monoclonal antibody preparation, or such can be achieved by using a gene transfer RNA viral vector of the present invention.
摘要翻译： 本发明提供了从具有增强的蛋白质表达能力的RNA病毒载体和RNA病毒载体增强蛋白质表达的方法。 通过从RNA病毒载体表达与AB5B蛋白质融合的蛋白质，本发明人通过显着地成功地提高了蛋白质表达水平。 有效的基因治疗，基因疫苗接种，单克隆抗体制备等可以通过使用本发明的基因转移RNA病毒载体来实现。
-
公开(公告)号：US20120087940A1
公开(公告)日：2012-04-12
申请号：US13126293
申请日：2009-10-30
申请人： Makoto Inoue , Koichi Saeki , Jun You , Toshiaki Tabata , Hitoshi Iwasaki , Tsugumine Shu , Mamoru Hasegawa
发明人： Makoto Inoue , Koichi Saeki , Jun You , Toshiaki Tabata , Hitoshi Iwasaki , Tsugumine Shu , Mamoru Hasegawa
IPC分类号： A61K31/7105 , A61P25/28 , C12N15/86 , A61K39/00
CPC分类号： A61K39/0007 , A61K38/00 , A61K2039/53 , A61K2039/545 , C07K14/4711 , C07K2319/55 , C12N2760/18843 , C12N2799/021 , C12N2799/04
摘要： The present invention provides methods for efficiently inducing anti-Aβ antibody and methods for preventing and treating Alzheimer's disease. The present inventors successfully induced anti-Aβ antibody in a highly efficient manner by administering an RNA viral vector that expresses a fusion protein between an AB5 toxin B subunit and an Aβ antigen peptide. Administration of the vector resulted in a significant increase of anti-Aβ antibody in plasma, and decrease in the Aβ level in brain tissues and decrease in the anti-Aβ antibody-positive area. The present invention enables more efficient vaccine gene therapy for preventing and treating Alzheimer's disease.
摘要翻译： 本发明提供了有效诱导抗Aβ的方法。 抗体和预防和治疗阿尔茨海默病的方法。 本发明人成功地诱导了抗A＆Bgr; 抗体，通过施用在AB5毒素B亚基和A＆bgr之间表达融合蛋白的RNA病毒载体以高效的方式; 抗原肽。 载体的施用导致抗A和Bgr的显着增加; 血浆中的抗体，A和Bgr的减少; 脑组织中的水平和抗A和Bgr的降低; 抗体阳性区。 本发明使得能够更有效地预防和治疗阿尔茨海默病的疫苗基因治疗。
-
公开(公告)号：US20100167341A1
公开(公告)日：2010-07-01
申请号：US12160573
申请日：2007-01-17
申请人： Jun You , Toshiaki Tabata , Makoto Inoue , Tsugumine Shu , Mamoru Hasegawa
发明人： Jun You , Toshiaki Tabata , Makoto Inoue , Tsugumine Shu , Mamoru Hasegawa
CPC分类号： C12N15/86 , C12N7/00 , C12N2760/18823 , C12N2760/18843 , C12P21/02
摘要： The present inventors devised a protein expression system with coexisting MiniSeV and SeV particles, and assessed the system for the ability to transfer a gene(s) of interest into target cells, and to express the gene(s) in the target cells. It was shown that the expression system of the present invention had a high ability to transfer a gene(s) of interest into target cells, and a high ability to express the gene(s) in the target cells.
摘要翻译： 本发明人设计了具有共存的MiniSeV和SeV颗粒的蛋白质表达系统，并评估了该系统将目的基因转移到靶细胞中的能力，并表达靶细胞中的基因。 结果表明，本发明的表达系统具有将目标基因转移到靶细胞中的高能力，以及在靶细胞中表达基因的高能力。
-
公开(公告)号：US20090246170A1
公开(公告)日：2009-10-01
申请号：US12302927
申请日：2007-05-31
申请人： Makoto Inoue , Yumiko Tokusumi , Hitoshi Iwasaki , Hiroto Hara , Toshiaki Tabata , Mamoru Hasegawa
发明人： Makoto Inoue , Yumiko Tokusumi , Hitoshi Iwasaki , Hiroto Hara , Toshiaki Tabata , Mamoru Hasegawa
IPC分类号： A61K38/20 , A61K31/7088 , A61K38/19 , A61K38/02 , A61P25/28
CPC分类号： A61K35/76 , A61K38/2026 , A61K38/2066 , A61K38/2086 , A61K48/00 , C07K14/5428 , C12N15/86 , C12N2760/18843 , A61K2300/00
摘要： The present invention provides novel therapeutic methods and agents for treating Alzheimer's disease. Specifically, the present invention relates to anti-inflammatory cytokines, anti-inflammatory cytokine genes, negative-strand RNA viral vectors carrying an anti-inflammatory cytokine gene, which are used for treating Alzheimer's disease or developing therapeutic agents for Alzheimer's disease. The present invention also provides pharmaceutical compositions for treating or preventing Alzheimer's disease, which comprise the cytokines or vectors. The present invention further provides methods for treating Alzheimer's disease, which comprise the step of administering an anti-inflammatory cytokine, or a vector such as a negative-strand RNA viral vector carrying an anti-inflammatory cytokine gene. The present invention enables novel gene therapies for Alzheimer's disease.
摘要翻译： 本发明提供治疗阿尔茨海默氏病的新型治疗方法和药剂。 具体而言，本发明涉及抗炎细胞因子，抗炎细胞因子基因，携带抗炎细胞因子基因的负链RNA病毒载体，其用于治疗阿尔茨海默病或开发阿尔茨海默氏病的治疗剂。 本发明还提供了用于治疗或预防阿尔茨海默病的药物组合物，其包含细胞因子或载体。 本发明还提供了治疗阿尔茨海默病的方法，其包括施用抗炎细胞因子的步骤，或携带抗炎细胞因子基因的载体如负链RNA病毒载体。 本发明使得能够进行阿尔茨海默病的新基因治疗。
-
公开(公告)号：US20090148425A1
公开(公告)日：2009-06-11
申请号：US12091686
申请日：2006-10-27
CPC分类号： C12N15/86 , A61K38/36 , A61K38/37 , A61K48/0058 , C12N2740/15043 , C12N2830/008
摘要： The present invention provides agents for treating blood coagulation abnormalities, which contain as an active ingredient a lentiviral vector carrying a blood coagulation factor gene operably linked to a promoter which induces platelet-specific expression. Agents for treating hemophilia A or hemophilia B are provided by application of the gene encoding Factor VIII or Factor IX. Blood coagulation abnormalities can be treated by gene therapy by infecting hematopoietic stem cells or such with the therapeutic agents of the present invention.
摘要翻译： 本发明提供了用于治疗血液凝固异常的药剂，其包含作为活性成分的携带凝血因子基因的慢病毒载体，所述凝血因子基因可操作地连接于诱导血小板特异性表达的启动子。 通过应用编码因子VIII或因子IX的基因提供治疗血友病A或血友病B的药剂。 可以通过用本发明的治疗剂感染造血干细胞的基因治疗来治疗血液凝固异常。
-
公开(公告)号：US06500943B2
公开(公告)日：2002-12-31
申请号：US10045428
申请日：2001-11-08
IPC分类号： C07H2104
CPC分类号： C12N9/1205 , C12N15/85 , C12N2830/00 , C12N2830/85
摘要： The present invention provides a DNA having promoter activity of Tec tyrosine kinase and a vector having incorporated within it the promoter to thereby enable a high level expression of an exogenous gene in hematopoietic stem cells and hepatic cells.
摘要翻译： 本发明提供了具有Tec酪氨酸激酶的启动子活性的DNA和在其内并入启动子的载体，从而能够在造血干细胞和肝细胞中高水平表达外源基因。
-
7.发明授权Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors 有权与使用SIV-PEDF载体的眼组织细胞凋亡变性相关疾病的治疗剂公开(公告)号：US08278284B2
公开(公告)日：2012-10-02
申请号：US11884738
申请日：2006-02-21
申请人： Masanori Miyazaki , Yoshikazu Yonemitsu , Yasuhiro Ikeda , Katsuo Sueishi , Toshiaki Tabata , Akihiro Iida , Yasuji Ueda , Mamoru Hasegawa
发明人： Masanori Miyazaki , Yoshikazu Yonemitsu , Yasuhiro Ikeda , Katsuo Sueishi , Toshiaki Tabata , Akihiro Iida , Yasuji Ueda , Mamoru Hasegawa
CPC分类号： A61K48/005 , A61K48/00 , C07K14/475 , C12N15/86 , C12N2740/15043 , C12N2740/15045 , C12N2810/6081
摘要： The present invention provides novel methods for treating diseases associated with apoptotic degeneration in ocular tissue cells by effective administration of pigment epithelium derived factor (PEDF). The present inventors studied PEDF as a means to prevent ganglion cell death, the final pathology of glaucoma. The present invention is particularly focused on SIV vectors for effective methods for delivering PEDF, and constructed an SIV-PEDF vector. When the SIV-PEDF vector was administered subretinally to an ischemia reperfusion model and NMDA-induced model, a significant suppression effect on ganglion cell death was observed. The present inventors therefore discovered that the SIV-PEDF vector is an effective pharmaceutical agent for treating diseases associated with apoptotic degeneration in ocular tissue cells, such as glaucoma.
摘要翻译： 本发明提供了通过有效施用色素上皮衍生因子（PEDF）来治疗与眼组织细胞凋亡变性相关的疾病的新方法。 本发明人研究了PEDF作为预防神经节细胞死亡，青光眼的最终病理学的手段。 本发明特别关注用于递送PEDF的有效方法的SIV载体，并构建了SIV-PEDF载体。 当将SIV-PEDF载体视觉上给予缺血再灌注模型和NMDA诱导的模型时，观察到对神经节细胞死亡的显着抑制作用。 因此本发明人发现SIV-PEDF载体是用于治疗与眼组织细胞如青光眼中凋亡变性相关的疾病的有效药剂。
-
8.发明申请Therapeutic Agents for Diseases Associated With Apoptotic Degeneration in Ocular Tissue Cells That Use SIV-PEDF Vectors 有权与使用SIV-PEDF载体的组织细胞凋亡相关的疾病治疗剂公开(公告)号：US20090233988A1
公开(公告)日：2009-09-17
申请号：US11884738
申请日：2006-02-21
申请人： Masanori Miyazaki , Yoshikazu Yonemitsu , Yasuhiro Ikeda , Katsuo Sueishi , Toshiaki Tabata , Akihiro Iida , Yasuji Ueda , Mamoru Hasegawa
发明人： Masanori Miyazaki , Yoshikazu Yonemitsu , Yasuhiro Ikeda , Katsuo Sueishi , Toshiaki Tabata , Akihiro Iida , Yasuji Ueda , Mamoru Hasegawa
IPC分类号： A61K31/711 , C12N15/63 , C12N7/01
CPC分类号： A61K48/005 , A61K48/00 , C07K14/475 , C12N15/86 , C12N2740/15043 , C12N2740/15045 , C12N2810/6081
摘要： The present invention provides novel methods for treating diseases associated with apoptotic degeneration in ocular tissue cells by effective administration of pigment epithelium derived factor (PEDF). The present inventors studied PEDF as a means to prevent ganglion cell death, the final pathology of glaucoma. The present invention is particularly focused on SIV vectors for effective methods for delivering PEDF, and constructed an SIV-PEDF vector. When the SIV-PEDF vector was administered subretinally to an ischemia reperfusion model and NMDA-induced model, a significant suppression effect on ganglion cell death was observed. The present inventors therefore discovered that the SIV-PEDF vector is an effective pharmaceutical agent for treating diseases associated with apoptotic degeneration in ocular tissue cells, such as glaucoma.
摘要翻译： 本发明提供了通过有效施用色素上皮衍生因子（PEDF）来治疗与眼组织细胞凋亡变性相关的疾病的新方法。 本发明人研究了PEDF作为预防神经节细胞死亡，青光眼的最终病理学的手段。 本发明特别关注用于递送PEDF的有效方法的SIV载体，并构建了SIV-PEDF载体。 当将SIV-PEDF载体视觉上给予缺血再灌注模型和NMDA诱导的模型时，观察到对神经节细胞死亡的显着抑制作用。 因此本发明人发现SIV-PEDF载体是用于治疗与眼组织细胞如青光眼中凋亡变性相关的疾病的有效药剂。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.038 秒)
